04l
For farmers and agricultural workers, the arrival of the cold air signals a shift in planting and harvesting schedules, as crops respond to the changing temperatures and daylight patterns. While some crops may benefit from the cooler weather, others may require additional protection or care to ensure a successful yield in the face of the approaching cold front.The exemption of land value added tax on the sale of ordinary residential properties is expected to have a positive impact on the real estate market in Henan province. It is anticipated to increase demand for housing, support property values, and drive economic growth in the region.Brawner denies taking over VP’s security
Nano Dimension Responds to Desktop Metal’s Lawsuit Regarding Merger AgreementCyberpunk 2077 fans around the world are buzzing with anticipation as CD Projekt Red has officially announced the upcoming 2.2 update for the highly acclaimed game. The Polish game development studio has promised a host of new features and improvements that are sure to enhance the player experience and breathe new life into the futuristic open-world adventure.
NEWARK — After a recount, the results of a Newark City Council race have held, with Jactina Arteaga headed toward victory with a four vote advantage. By Friday afternoon, Arteaga had a 0.1% lead, with 6,446 votes to Julie Del Catancio’s 6,442 votes. The Alameda County Registrar of Voters manually recounted all of the race’s ballots by Friday afternoon and the results appeared to hold the same, an official said Friday. Tim DuPuis, the Alameda County registrar, said Friday that he personally made the decision to review the race’s results because it was within 10 votes of separation – the closest race in the county. The results of the recount appeared to hold, Dupuis said Friday. The only other tight race in the county, he added, was the Fremont District 6 council race where Raymond Liu had a 36-vote lead over incumbent Teresa Cox. At one point, the contest had been as close as 12 votes before more ballots were counted.Dupuis said he did not elect to recount that race. Arteaga received a bachelor’s degree in business administration from Cal State University, Hayward. She has previous experience as a child support officer for San Mateo County, in finance and public safety administration in San Mateo County District Attorney Steve Wagstaffe’s office and as an assistant agency director with the Social Services Agency. “Although it has been a roller coaster with the results these past few weeks, it is important that every vote gets counted. I’m glad the ROV is doing a manual count and I hope that I remain in the lead,” Arteaga said in a statement Friday before the recount was completed. “Either way the voters have spoken and we will have new leadership on the council beginning in December.” The latest campaign finance records show Arteaga raised $14,902 through October, mostly through small donations, including a $2,500 personal loan. She spent $5,820, largely on print ads and other campaign advertising materials. “It seems like what people really want to see is that they’re safe, that their families are safe, and that we’re responsible,” Del Catancio said in an interview Friday. “I feel like I’d fit in wholeheartedly because I really love Newark, I’m a long term resident here and I also work in the area.” Del Catancio received a law degree from the University of San Francisco School of Law and a master’s degree in administration from the University of Kansas. She is currently a Newark planning commissioner and educator in the Newark Unified School District. “Win or lose, I feel like we put our heart and soul into it and we tried the best that we could. And so I think that it’s really up to the people,” Del Catancio added. “The fact is that in any race, you set out, you try your hardest, you meet the people and they make a decision. We’ll see how it goes, fingers crossed.” The registrar’s office expects to certify the Nov. 5 election results in December.
The fund, shrouded in secrecy and known only by its initials, has been strategically positioning itself in various sectors of the Chinese economy, from tech giants like Alibaba and Tencent to emerging industries such as green energy and electric vehicles. Its savvy investment decisions have paid off handsomely, with the fund's portfolio experiencing a meteoric rise in value, reaching the 10-billion mark in floating profits.
One of the key driving factors behind this resurgence is the renewed focus on technology innovation. In today's rapidly evolving digital landscape, companies that prioritize innovation are well-positioned to not only survive but thrive. The recent advancements in areas such as artificial intelligence, augmented reality, and blockchain technology have further fueled investor interest in tech-driven companies.
Taiwan Semiconductor Manufacturing Company (TSMC) has recently emerged victorious in a crucial battle that could potentially redefine the landscape of the semiconductor industry. The leading semiconductor foundry announced that it has successfully secured a significant number of customer orders for its cutting-edge 3nm process technology, marking a major milestone in its technological advancement.
None
NEW YORK (AP) — A triptych of criminal charges paints a searing, sometimes disparate portrait of the man accused of ambushing and killing UnitedHealthcare’s CEO Brian Thompson as the executive arrived at a Manhattan hotel for his company’s annual investor conference. Read this article for free: Already have an account? To continue reading, please subscribe: * NEW YORK (AP) — A triptych of criminal charges paints a searing, sometimes disparate portrait of the man accused of ambushing and killing UnitedHealthcare’s CEO Brian Thompson as the executive arrived at a Manhattan hotel for his company’s annual investor conference. Read unlimited articles for free today: Already have an account? NEW YORK (AP) — A triptych of criminal charges paints a searing, sometimes disparate portrait of the man accused of ambushing and killing UnitedHealthcare’s CEO Brian Thompson as the executive arrived at a Manhattan hotel for his company’s annual investor conference. Filed separately in state courts in New York and Pennsylvania, and a federal court in Manhattan, and totaling 20 counts, the charges brand Luigi Mangione as both a terrorist and a stalker, accuse him of carrying a ghost gun and a fake ID, and enable prosecutors to seek life in state prison and the federal death penalty. On Monday, in the last of three court appearances in five days, the 26-year-old Mangione pleaded not guilty in New York state court to an indictment charging him with 11 counts in connection with the Dec. 4 killing, including murder as a crime of terrorism. Mangione’s state court arraignment followed back-to-back hearings last Thursday in Pennsylvania, where he was arrested Dec. 9, and in federal court in Manhattan, where a judge ordered him jailed without bail on murder, gun and stalking charges. Mangione’s lawyer, Karen Friedman Agnifilo, has argued that the terrorism allegations in the state case and stalking charges in the federal complaint appear to be at odds. Prosecutors are treating him “like a human ping-pong ball and “some sort of spectacle,” she said in court Monday. Here’s a look at the cases and the charges involved: New York: 11 counts including a terrorism offense Mangione’s state court indictment alleges he killed Thompson to “intimidate or coerce” a group of people and influence government policy “by intimidation or coercion.” It includes three counts of murder, alleging Mangione killed “in furtherance of terrorism,” as an act of terrorism and with intent, and carries a maximum sentence of life in prison. Manhattan District Attorney Alvin Bragg, whose office is prosecuting the case, said last week that the midtown Manhattan ambush “was a killing that was intended to evoke terror.” The indictment also charges Mangione with seven gun-related counts and one count related to a fake New Jersey driver’s license that prosecutors said he used to check into a Manhattan hostel when he arrived in the city 10 days before the killing. Prosecutors say they anticipate the state case will be the first to go to trial. After his arraignment Monday, Mangione was returned to a federal jail in Brooklyn while state and federal authorities sort out where he’ll be detained while the state case plays out. Federal: 4 counts including death-penalty eligible charge A day after Bragg announced Mangione’s state indictment, federal prosecutors upped the ante with a four-count criminal complaint that could bring the death penalty if he is convicted. The complaint charges two counts of stalking and one count each of murder through use of a firearm, and a firearms offense. Murder through use of a firearm carries the possibility of the death penalty, though prosecutors have not said if they will seek it. Mangione made an initial appearance on the charges before a federal magistrate judge last Thursday but was not required to enter a plea. The U.S. attorney’s office in Manhattan has until mid-January to secure an indictment from a federal grand jury. According to the federal complaint, Mangione had a spiral notebook in which he expressed hostility toward the health insurance industry and wealthy executives. UnitedHealthcare is the largest health insurer in the U.S., though the company said Mangione was never a client. Among the entries, the complaint said, was one from August that said “the target is insurance” because “it checks every box” and one from October that describes an intent to “wack” an insurance company CEO. Pennsylvania: 5 counts, including gun possession and false ID Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. Mangione was arrested on Dec. 9 in Altoona, Pennsylvania, about 230 miles (about 370 kilometers) west of New York City, and initially charged there with possession of an unlicensed firearm, forgery and providing false identification to police. Blair County Peter Weeks said last week that he intends to keep the case active and plans to revisit it once Mangione’s murder charges are adjudicated. Mangione was arrested while eating breakfast at an Altoona McDonald’s after a customer noticed that he looked like the person in surveillance photos that police were circulating of Thompson’s killer. Officers found a gun that matched the one used in the shooting, a fake ID and writings that expressed hostility toward the health insurance industry, prosecutors said. Hours later, the Manhattan DA’s office filed paperwork for a warrant for Mangione’s arrest on a murder charge. Mangione, who was held without bail in Pennsylvania, headed off a protracted extradition fight by agreeing to be flown to New York last Thursday. Advertisement AdvertisementCold Agglutinin Disease Pipeline Review 2024: Clinical Trials Updates, Therapies, Mechanism of Action, Route of Administration, and Developments | Apellis Pharmaceuticals, Novartis, Incyte corporation, Sanofi, Alexion Pharmaceuticals, Novartis 11-27-2024 07:43 PM CET | Health & Medicine Press release from: DelveIinsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cold Agglutinin Disease pipeline constitutes 5+ key companies continuously working towards developing 5+ Cold Agglutinin Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Cold Agglutinin Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cold Agglutinin Disease Market. The Cold Agglutinin Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Cold Agglutinin Disease Pipeline Report: https://www.delveinsight.com/sample-request/cold-agglutinin-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Cold Agglutinin Disease treatment therapies with a considerable amount of success over the years. •Cold Agglutinin Disease companies working in the treatment market are Apellis Pharmaceuticals, Novartis, Incyte corporation, Sanofi, Alexion Pharmaceuticals, Novartis, and others, are developing therapies for the Cold Agglutinin Disease treatment •Emerging Cold Agglutinin Disease therapies in the different phases of clinical trials are- Pegcetacoplan, Iptacopan, Parsaclisib, SAR445088, Eculizumab, sutimlimab (BIVV009, Iptacopan, and others are expected to have a significant impact on the Cold Agglutinin Disease market in the coming years. •In March 2024, Alpine Immune Sciences, Inc. has initiated the RUBY-4 (NCT05757570) study, a multi-cohort, open-label Phase 1b trial evaluating povetacicept in immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease. In this study, povetacicept is administered subcutaneously for up to 48 weeks. Key endpoints include blood cell counts, durable responses, and levels of disease-related autoantibodies. Cold Agglutinin Disease Overview Cold Agglutinin Disease (CAD) is a rare autoimmune disorder in which the immune system produces antibodies, called cold agglutinins, that mistakenly target and destroy red blood cells at low temperatures. This leads to a type of anemia called hemolytic anemia. Get a Free Sample PDF Report to know more about Cold Agglutinin Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/cold-agglutinin-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Cold Agglutinin Disease Drugs Under Different Phases of Clinical Development Include: •Pegcetacoplan: Apellis Pharmaceuticals •Iptacopan: Novartis •Parsaclisib: Incyte corporation •SAR445088: Sanofi •Eculizumab: Alexion Pharmaceuticals •sutimlimab (BIVV009): Sanofi •Iptacopan: Novartis Cold Agglutinin Disease Route of Administration Cold Agglutinin Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Oral •Parenteral •Intravenous •Subcutaneous •Topical Cold Agglutinin Disease Molecule Type Cold Agglutinin Disease Products have been categorized under various Molecule types, such as •Monoclonal Antibody •Peptides •Polymer •Small molecule •Gene therapy Cold Agglutinin Disease Pipeline Therapeutics Assessment •Cold Agglutinin Disease Assessment by Product Type •Cold Agglutinin Disease By Stage and Product Type •Cold Agglutinin Disease Assessment by Route of Administration •Cold Agglutinin Disease By Stage and Route of Administration •Cold Agglutinin Disease Assessment by Molecule Type •Cold Agglutinin Disease by Stage and Molecule Type DelveInsight's Cold Agglutinin Disease Report covers around 5+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Cold Agglutinin Disease product details are provided in the report. Download the Cold Agglutinin Disease pipeline report to learn more about the emerging Cold Agglutinin Disease therapies at: https://www.delveinsight.com/sample-request/cold-agglutinin-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Cold Agglutinin Disease Therapeutics Market include: Key companies developing therapies for Cold Agglutinin Disease are - Sanofi, Bioverativ, Sobi, Apellis Pharmaceuticals, Novartis, Incyte Corporation, and others. Cold Agglutinin Disease Pipeline Analysis: The Cold Agglutinin Disease pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Cold Agglutinin Disease with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cold Agglutinin Disease Treatment. •Cold Agglutinin Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Cold Agglutinin Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cold Agglutinin Disease market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Cold Agglutinin Disease drugs and therapies- https://www.delveinsight.com/sample-request/cold-agglutinin-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Cold Agglutinin Disease Pipeline Market Drivers •Several organizations and companies like Cold agglutinin disease foundation and Sanofi Genzyme are raising awareness about the disease which can lead to increased patient pool. Cold Agglutinin Disease Pipeline Market Barriers •Mild anemic patients because of CAD don't have such a pharmaceutical treatment option, so there is an unsaid need for the drugs in mild anemic patients. Scope of Cold Agglutinin Disease Pipeline Drug Insight •Coverage: Global •Key Cold Agglutinin Disease Companies: Apellis Pharmaceuticals, Novartis, Incyte corporation, Sanofi, Alexion Pharmaceuticals, Novartis, and others •Key Cold Agglutinin Disease Therapies: Pegcetacoplan, Iptacopan, Parsaclisib, SAR445088, Eculizumab, sutimlimab (BIVV009, Iptacopan, and others •Cold Agglutinin Disease Therapeutic Assessment: Cold Agglutinin Disease current marketed and Cold Agglutinin Disease emerging therapies •Cold Agglutinin Disease Market Dynamics: Cold Agglutinin Disease market drivers and Cold Agglutinin Disease market barriers Request for Sample PDF Report for Cold Agglutinin Disease Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/cold-agglutinin-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Cold Agglutinin Disease Report Introduction 2. Cold Agglutinin Disease Executive Summary 3. Cold Agglutinin Disease Overview 4. Cold Agglutinin Disease- Analytical Perspective In-depth Commercial Assessment 5. Cold Agglutinin Disease Pipeline Therapeutics 6. Cold Agglutinin Disease Late Stage Products (Phase II/III) 7. Cold Agglutinin Disease Mid Stage Products (Phase II) 8. Cold Agglutinin Disease Early Stage Products (Phase I) 9. Cold Agglutinin Disease Preclinical Stage Products 10. Cold Agglutinin Disease Therapeutics Assessment 11. Cold Agglutinin Disease Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Cold Agglutinin Disease Key Companies 14. Cold Agglutinin Disease Key Products 15. Cold Agglutinin Disease Unmet Needs 16 . Cold Agglutinin Disease Market Drivers and Barriers 17. Cold Agglutinin Disease Future Perspectives and Conclusion 18. Cold Agglutinin Disease Analyst Views 19. Appendix 20. About DelveInsight Related Reports: Cold Agglutinin Disease Market https://www.delveinsight.com/report-store/cold-agglutinin-disease-cad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Cold Agglutinin Disease Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Cold Agglutinin Disease Epidemiology https://www.delveinsight.com/report-store/cold-agglutinin-disease-cad-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Cold Agglutinin Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Latest Reports: Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight •Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market •Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market •Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market •Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market •Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight •Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market •Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.
Through the lens of society's judgmental gaze, Lin Jing'en emerged as a paradoxical figure - a fallen star who retained a sense of pride and self-respect amidst the harsh realities of life on the streets. His refusal to conform to the stereotype of the pitiful beggar served as a testament to his inner strength and resilience, qualities that had been overshadowed by the glitz and glamour of his former life.However, alongside cooperation, the former Spanish Foreign Minister also underscored the challenges that exist in the China-EU relationship. Differences in values, governance systems, and human rights issues have at times strained relations between the two sides. The former Spanish Foreign Minister emphasized the need for open and frank discussions to address these differences and find common ground where possible.
In addition to the thrilling matches, the WTT Singapore Grand Slam also offers a range of off-court activities and events for fans to enjoy. From autograph sessions with players to interactive tennis clinics and fan meet-and-greets, there is something for everyone to participate in and get involved with the tennis community. The tournament not only celebrates the sport of tennis but also fosters a sense of camaraderie and connection among fans and players alike.
Why Daniel Jones signing with the Vikings makes a world of sense for both sides
In conclusion, the recent resurgence of the real estate market can be attributed to a combination of multiple policies and factors working in tandem to fuel growth and recovery. By leveraging the opportunities presented by favorable policies, technological advancements, and changing market dynamics, the real estate sector is poised for a bright future ahead.Furthermore, the meeting has been seen as a reaffirmation of the government's commitment to deepening reform and opening up. Institutions view this as a positive signal that China remains dedicated to further liberalizing its economy and promoting a more market-driven approach to growth.
NEW ORLEANS, La. (AP) — A Louisiana civil court judge on Monday halted state agencies’ plans to forcibly clear homeless encampments in New Orleans. Orleans Parish Civil District Court Judge Ethel Julien issued a temporary restraining order blocking state police and two other agencies from evicting homeless people from their encampments in New Orleans or seizing their property without following city laws and due process. Republican Gov. Jeff Landry had earlier this month for the City of New Orleans to remove a large encampment before Thanksgiving and warned he would intervene if the city did not comply. “If a judge believes that people have a right to be on whatever public space they choose, maybe that judge should have them move into her chambers and courtroom,” Landry said after the judge issued the restraining order Monday. Louisiana State Police spokesperson Sgt. Katharine Stegall said the agency’s legal team and the state Attorney General’s Office are reviewing the order. State police have “promptly halted activities” and are “complying with the restrictions” of the order, Stegall said. Landry and New Orleans officials have over how to address the issue of homelessness in the city. New Orleans City Councilmember Lesli Harris said Monday that directing more resources towards moving homeless people into stable housing was “infinitely more effective than punitive sweeps” of encampments. “Coordination between the government and service providers on the housing of people is imperative, and continuously moving people only makes it that much harder to house them,” Harris said. But the governor has pushed to clear homeless encampments. In late October, Louisiana State Police, the Department of Wildlife and Fisheries and the Department of Transportation and Development converged on a homeless encampment under a highway to remove and relocate dozens of people in the nearby Superdome. Some people who had been away at the time of the clearances returned to the area to find they had lost their personal property including family heirlooms, identification documents and medication, according to testimony in court documents. City officials and advocates for homeless people decried the evictions and said they disrupted ongoing efforts to secure long-term housing for these individuals because they became harder to locate. A judge later preventing more clearances but declined to extend it beyond early November after lawyers representing the state police indicated in court that removals tied to the Taylor Swift concerts had ceased. But on Friday, homeless people began receiving flyers from state police officers ordering them to leave their encampments within 24 hours, according to a motion for relief filed on behalf of two homeless plaintiffs by the Southern Poverty Law Center and two other legal groups. The planned sweeps preceded the Bayou Classic football game on Saturday between Southern University and Grambling State University at the Superdome. “Your presence is considered a violation,” the flyers stated, according to the motion for relief. However, they were halted by the new temporary restraining order. On Dec. 3, the judge is scheduled to deliberate on whether to issue a preliminary injunction against the three state agencies. “The vulnerable people with disabilities who make up the vast majority of people living in the street deserve to be treated with sensitivity and compassion,” said Joe Heeren-Mueller, director of community engagement for Unity of Greater New Orleans, a homeless outreach organization. There are about 1,450 homeless people in New Orleans and neighboring Jefferson Parish, according to a January survey by the nonprofit Unity of Greater New Orleans. The city has committed to securing housing for these individuals by the end of 2025. _____ Brook is a corps member for The Associated Press/Report for America Statehouse News Initiative. is a nonprofit national service program that places journalists in local newsrooms to report on undercovered issues. Follow Brook on the social platform X: @jack_brook96 Jack Brook, The Associated PressBAKU, Nov 25 — Rich countries’ promise of US$300 billion a year in climate finance brought fury at talks in Baku from poor nations that found it too paltry, but it also shows a shift in global political realities. The two-week marathon COP29 climate conference opened days after the decisive victory in the US presidential election of Donald Trump, a sceptic both of climate change and foreign aid. In the new year, Germany, Canada and Australia all hold elections in which conservatives less supportive of green policies stand chances of victory. Britain is an exception, with the new Labour government putting climate high back on the agenda, but in much of the West, concerns about inflation and budgetary shocks from Russia’s invasion of Ukraine have dented enthusiasm for aggressive climate measures. At COP29, Germany and the European Union maintained their roles championing climate but also advocated a noticeably practical approach on how much money historical polluters should give poorer countries. “We live in a time of truly challenging geopolitics, and we should simply not have the illusion” otherwise, European climate commissioner Wopke Hoekstra told bleary-eyed delegates at COP29’s pre-dawn closing session Sunday, as activists in the back loudly coughed to drown him out. But he vowed leadership by Europe, hailing COP29 as “the start of a new era for climate finance”. German Foreign Minister Annalena Baerbock, a Green party member and longtime climate advocate, called for flexibility on ways to provide funding. Europe should “live up to its responsibilities, but in a way that it doesn’t make promises it can’t keep”, she said. Avinash Persaud, special advisor on climate change to the president of the Inter-American Development Bank, called the final deal “the boundary between what is politically achievable today in developed countries and what would make a difference in developing countries”. Activists say that climate funding is a duty, not choice, for wealthy nations whose decades of greenhouse gas emissions most contributed to the crisis that most hits the poorest. This year is again set to be the hottest on record on the planet. Just since COP29, deadly storms have battered the Philippines and Honduras, and Ecuador declared a national emergency due to drought and forest fires. ‘Creative accounting’? Wealthy historic emitters’ promise of US$300 billion a year by 2035 is a step up from an expiring commitment of US$100 billion annually, but all sides acknowledge it is not enough. The COP29 agreement cites the need for US$1.3 trillion per year, meaning a whopping US$1 trillion a year needs to come from elsewhere. Even within the US$300 billion commitment, some activists see too much wiggle room. “It is, to some extent, almost an empty promise,” said Mariana Paoli, the global advocacy lead at London-based development group Christian Aid. She described the target as “creative accounting”, saying there was not enough clarity on how much money would come from public funds and in grants rather than loans. She acknowledged the politics of the moment but said that wealthy nations had options such as taxation on fossil fuel companies. “There is a backlash because there is no political will,” she said. Role for multinational banks In one closely scrutinised part of the Baku deal, countries will be able to count climate finance through international financial institutions toward the US$300 billion goal. The text states that it is “voluntary” — potentially opening the way to include China, which is the world’s largest emitter but refuses to have requirements like long-developed countries. In a joint statement at COP29, multilateral development banks led by the Washington-based World Bank Group but also including the Beijing-based Asian Infrastructure Investment Bank — which has long faced US criticism — expected that they together can provide US$120 billion annually in climate financing and mobilise another US$65 billion from the private sector by 2030. Melanie Robinson, director of the global climate program at the World Resources Institute, said there were good reasons to rely on multinational development banks, including how much capital they can leverage and their tools to advance green policies. “They are the most effective way to turn each dollar of finance into impact on the ground,” she said. She agreed that the US$300 billion was insufficient but added, “It’s a down payment on what we need.” Beyond the debate on dollar figures, she pointed to an initiative within the G20 by Brazil, which holds COP30 next year, to reform financial institutions so as to incorporate debtor nations as well as climate concerns. “There is really a much bigger opportunity for us — which is shifting the whole financial system,” she said. — AFP